Eli Lilly and Nvidia both just posted stunning quarters riding two of the biggest secular waves in markets today, but a $10,000 bet can only tilt one way. Which secular story holds the sharper edge heading into 2026?

Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.

Eli Lilly valuation remains debated as cash-flow strength, pharmaceutical growth, pipeline progress and recent market weakness reshape the story.

Cloverleaf Bio has closed an upsized and oversubscribed $33 million seed financing to advance its engineered transfer RNA, or tRNA, therapeutic platform and develop new treatments for cancer. The round was led by 4BIO Capital and included strategic investments from AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund, along with Draper Associates, Mission BioCapital and American Cancer Society BrightEdge.

It’s Eli Lilly vs. RFK Jr. in a battle in front of the 7th Circuit Court of Appeals over the rules around Retatrutide.

Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand and strategic moves, while Stratus advances asset sales.

Clinical trials continue to drive drug development in modern medicine, yet most Americans never hear about them from the person they trust most with their health. According to a 2025 survey, only 8 percent had heard about clinical trials from their provider. A conversation that never happens is an option a patient never has.

Eli Lilly failed to plausibly allege that a physician group and pharmacy conspired to falsely advertise compounded versions of its diabetes and weight loss drugs, but can continue with allegations they conspired to unfairly compete with Lilly, a California federal judge held.

Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand, strategic moves and growth prospects despite key risks.

Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.

On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]

A study sponsored by Eli Lilly and Company (Lilly) shows that chronic illness is historically underrepresented on screen, while a growing coalition of studios, researchers, and patient advocates work to change that reality.

Kura Oncology spins out Caspian Therapeutics to apply its menin inhibitor expertise to diabetes — with Eli Lilly validating the science.